Chemical Debt Financing Perks Up (ICIS Chemical Business February 21 – February 27, 2025)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have rebounded chemical debt financings and the outlook for 2025.
Biopharma Business Check – Financing and Review (Pharmaceutical Executive, February 2025)
Young & Partners shares proprietary analysis of the stock market and funding environment in Biotech and Pharma and the outlook for 2025.
Global M&A Treads Water
Young & Partners shares proprietary analysis of the Chemicals M&A market and their outlook for 2025.
Divestitures in the Current Environment
Young & Partners shares proprietary analysis of the Chemicals M&A market and proposes questions for Chemicals owners to think over as significant asset rationalization occurs globally.
Reflections on 2024 and Outlook – Stock Market and Funding
Young & Partners shares proprietary analysis of the stock market and funding environment in Biotech and Pharma and the outlook for 2025.
Reflections on 2024 and Outlook – Senior Management Approach to M&A
Young & Partners shares proprietary analysis and outlook of how managers and executive should approach Biotech and Pharma M&A market in 2025.
Reflections on 2024 and Outlook – Biotech and Pharma M&A
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have affected the Biotech and Pharma M&A market in 2024 and the outlook for 2025.
Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading? (Pharmaceutical Executive)
Pharmaceutical Executive shares Peter Marks' comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-brave-new-world-where-heading-
Industry Restructuring & Inorganic Growth Through an Era of Chronic Oversupply (World Chemical Forum Speech September 10, 2024)
Young & Partners shares their thoughts and analysis of the global oversupply and uncertainties that have impacted the chemical markets. The presentation addresses the era of chronic oversupply, strategic assessments, M&A market conditions, and Strategic and M&A alternatives.